Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB)

被引：3
|
作者：
Lipsitz, E. G.
Nguyen, V.
Zhao, H.
Ecsedy, J.
Maris, J. M.
Adamson, P. C.
Mosse, Y. P.
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Childrens Hosp, Philadelphia, PA 19104 USA
[3] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.10593
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10593
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Cervantes, Andres
    Elez, Elena
    Roda, Desamparados
    Ecsedy, Jeffrey
    Macarulla, Teresa
    Venkatakrishnan, Karthik
    Rosello, Susana
    Andreu, Jordi
    Jung, JungAh
    Sanchis-Garcia, Juan Manuel
    Piera, Adelaida
    Blasco, Inma
    Manos, Laura
    Perez-Fidalgo, Jose-Alejandro
    Fingert, Howard
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4764 - 4774
  • [42] The effect of food on the pharmacokinetics of the investigational Aurora A kinase (AAK) inhibitor, alisertib (MLN8237), in patients (pts) with advanced solid tumors or lymphomas
    Zhou, X.
    Bauer, T. M.
    Goel, S.
    Sarantopoulos, J.
    Zhang, B.
    Kelly, V.
    Mertz, J.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 109 - 109
  • [43] Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Fare, Elena
    Marchlano, Alfonso
    Crippa, Flavlo
    Togllardi, Elena
    Daldone, Maria Grazla
    Gianni, Alessandro M.
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Temozolomide (TMZ) and Irinotecan (IRN) as a Maintenance Therapy for MYCN Non-Amplified High-Risk Neuroblastoma
    Isshiki, Kyohei
    Kiyotani, Chikako
    Matsukawa, Yukihiro
    Sugawa, Masahiro
    Mizuno, Takanori
    Tsujimoto, Shinnichi
    Sakamoto, Kennichi
    Uchiyama, Meri
    Osumi, Tomoo
    Shioda, Yoko
    Kato, Motohiro
    Terashima, Keita
    Tomizawa, Daisuke
    Hishiki, Tomoro
    Yoshioka, Takako
    Fuji, Hiroshi
    Miyazaki, Osamu
    Kitamura, Masayuki
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S107 - S108
  • [45] A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC)
    Necchi, Andrea
    Raggi, Daniele
    Lo Vullo, Salvatore
    Mariani, Luigi
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Perrone, Federica
    Pelosi, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [46] Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid Tumors
    Graff, Julie N.
    Higano, Celestia S.
    Hahn, Noah M.
    Taylor, Matthew H.
    Zhang, Bin
    Zhou, Xiaofei
    Venkatakrishnan, Karthik
    Leonard, E. Jane
    Sarantopoulos, John
    CANCER, 2016, 122 (16) : 2524 - 2533
  • [47] Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
    Kozyreva, Varvara K.
    Kiseleva, Anna A.
    Ice, Ryan J.
    Jones, Brandon C.
    Loskutov, Yuriy V.
    Matalkah, Fatimah
    Smolkin, Matthew B.
    Marinak, Kristina
    Livengood, Ryan H.
    Salkeni, Mohamad A.
    Wen, Sijin
    Hazard, Hannah W.
    Layne, Ginger P.
    Walsh, Callee M.
    Cantrell, Pamela S.
    Kilby, Greg W.
    Mahavadi, Sricharan
    Shah, Neal
    Pugacheva, Elena N.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1809 - 1822
  • [48] Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237
    Sloane, Dominic A.
    Trikic, Michael Z.
    Chu, Matthew L. H.
    Lamers, Maria B. A. C.
    Mason, Clive S.
    Mueller, Ilka
    Savory, Wendy J.
    Williams, David H.
    Eyers, Patrick A.
    ACS CHEMICAL BIOLOGY, 2010, 5 (06) : 563 - 576
  • [49] Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis
    Gangat, Naseema
    Stein, Brady Lee
    Marinaccio, Christian
    Swords, Ronan
    Watts, Justin M.
    Gurbuxani, Sandeep
    Frankfurt, Olga
    Altman, Jessica K.
    Wen, Jeremy Q.
    Farnoud, Noushin
    Famulare, Christopher
    Patel, Akshar
    Tapia, Roberto
    Handlogten, Amy
    Dinh, Yvonne Trang
    Englund, Kristen
    Patel, Shradha
    Nobrega, Juan Carlos
    Tejera, Dalissa
    Thomassen, Amber
    Stein, Harald
    Gao, Juehua
    Ji, Peng
    Rampal, Raajit K.
    Giles, Francis J.
    Tefferi, Ayalew
    Crispino, John D.
    BLOOD, 2018, 132
  • [50] MLN8237, A NOVEL ORALLY ACTIVE AURORA A KINASE INHIBITOR, IS HIGHLY ACTIVE ALONE AND IN COMBINATION WITH CYTARABINE IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
    Kelly, R.
    Swords, R.
    Mahalingam, D.
    Nawrocki, S.
    Medina, E.
    Smith, S.
    Padmanabhan, S.
    Ecsedy, J.
    Giles, F.
    Carew, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 339 - 340
12345